arXiv ScienceSearch

arXiv · 2306.00838

The Brain Tumor Segmentation (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI

Ahmed W. Moawad·Anastasia Janas·Ujjwal Baid·Divya Ramakrishnan·Rachit Saluja·Nader Ashraf·Nazanin Maleki·Leon Jekel·Nikolay Yordanov·Pascal Fehringer·Athanasios Gkampenis·Raisa Amiruddin·Amirreza Manteghinejad·Maruf Adewole·Jake Albrecht·Udunna Anazodo·Sanjay Aneja·Syed Muhammad Anwar·Timothy Bergquist·Veronica Chiang·Verena Chung·Gian Marco Conte·Farouk Dako·James Eddy·Ivan Ezhov·Nastaran Khalili·Keyvan Farahani·Juan Eugenio Iglesias·Zhifan Jiang·Elaine Johanson·Anahita Fathi Kazerooni·Florian Kofler·Kiril Krantchev·Dominic LaBella·Koen Van Leemput·Hongwei Bran Li·Marius George Linguraru·Xinyang Liu·Zeke Meier·Bjoern H Menze·Harrison Moy·Klara Osenberg·Marie Piraud·Zachary Reitman·Russell Takeshi Shinohara·Chunhao Wang·Benedikt Wiestler·Walter Wiggins·Umber Shafique·Klara Willms·Arman Avesta·Khaled Bousabarah·Satrajit Chakrabarty·Nicolo Gennaro·Wolfgang Holler·Manpreet Kaur·Pamela LaMontagne·MingDe Lin·Jan Lost·Daniel S. Marcus·Ryan Maresca·Sarah Merkaj·Gabriel Cassinelli Pedersen·Marc von Reppert·Aristeidis Sotiras·Oleg Teytelboym·Niklas Tillmans·Malte Westerhoff·Ayda Youssef·Devon Godfrey·Scott Floyd·Andreas Rauschecker·Javier Villanueva-Meyer·Irada Pfluger·Jaeyoung Cho·Martin Bendszus·Gianluca Brugnara·Justin Cramer·Gloria J. Guzman Perez-Carillo·Derek R. Johnson·Anthony Kam·Benjamin Yin Ming Kwan·Lillian Lai·Neil U. Lall·Fatima Memon·Mark Krycia·Satya Narayana Patro·Bojan Petrovic·Tiffany Y. So·Gerard Thompson·Lei Wu·E. Brooke Schrickel·Anu Bansal·Frederik Barkhof·Cristina Besada·Sammy Chu·Jason Druzgal·Alexandru Dusoi·Luciano Farage·Fabricio Feltrin

Abstract

The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and characterizes the challenging cases that impacted the performance of the winning algorithms. Untreated brain metastases on standard anatomic MRI sequences (T1, T2, FLAIR, T1PG) from eight contributed international datasets were annotated in stepwise method: published UNET algorithms, student, neuroradiologist, final approver neuroradiologist. Segmentations were ranked based on lesion-wise Dice and Hausdorff distance (HD95) scores. False positives (FP) and false negatives (FN) were rigorously penalized, receiving a score of 0 for Dice and a fixed penalty of 374 for HD95. Eight datasets comprising 1303 studies were annotated, with 402 studies (3076 lesions) released on Synapse as publicly available datasets to challenge competitors. Additionally, 31 studies (139 lesions) were held out for validation, and 59 studies (218 lesions) were used for testing. Segmentation accuracy was measured as rank across subjects, with the winning team achieving a LesionWise mean score of 7.9. Common errors among the leading teams included false negatives for small lesions and misregistration of masks in space.The BraTS-METS 2023 challenge successfully curated well-annotated, diverse datasets and identified common errors, facilitating the translation of BM segmentation across varied clinical environments and providing personalized volumetric reports to patients undergoing BM treatment.

Explore related subjects

Keep this discovery

BibTeXRIS

Ahmed W. Moawad, Anastasia Janas, Ujjwal Baid, Divya Ramakrishnan, Rachit Saluja, Nader Ashraf, Nazanin Maleki, Leon Jekel, Nikolay Yordanov, Pascal Fehringer, Athanasios Gkampenis, Raisa Amiruddin, Amirreza Manteghinejad, Maruf Adewole, Jake Albrecht, Udunna Anazodo, Sanjay Aneja, Syed Muhammad Anwar, Timothy Bergquist, Veronica Chiang, Verena Chung, Gian Marco Conte, Farouk Dako, James Eddy, Ivan Ezhov, Nastaran Khalili, Keyvan Farahani, Juan Eugenio Iglesias, Zhifan Jiang, Elaine Johanson, Anahita Fathi Kazerooni, Florian Kofler, Kiril Krantchev, Dominic LaBella, Koen Van Leemput, Hongwei Bran Li, Marius George Linguraru, Xinyang Liu, Zeke Meier, Bjoern H Menze, Harrison Moy, Klara Osenberg, Marie Piraud, Zachary Reitman, Russell Takeshi Shinohara, Chunhao Wang, Benedikt Wiestler, Walter Wiggins, Umber Shafique, Klara Willms, Arman Avesta, Khaled Bousabarah, Satrajit Chakrabarty, Nicolo Gennaro, Wolfgang Holler, Manpreet Kaur, Pamela LaMontagne, MingDe Lin, Jan Lost, Daniel S. Marcus, Ryan Maresca, Sarah Merkaj, Gabriel Cassinelli Pedersen, Marc von Reppert, Aristeidis Sotiras, Oleg Teytelboym, Niklas Tillmans, Malte Westerhoff, Ayda Youssef, Devon Godfrey, Scott Floyd, Andreas Rauschecker, Javier Villanueva-Meyer, Irada Pfluger, Jaeyoung Cho, Martin Bendszus, Gianluca Brugnara, Justin Cramer, Gloria J. Guzman Perez-Carillo, Derek R. Johnson, Anthony Kam, Benjamin Yin Ming Kwan, Lillian Lai, Neil U. Lall, Fatima Memon, Mark Krycia, Satya Narayana Patro, Bojan Petrovic, Tiffany Y. So, Gerard Thompson, Lei Wu, E. Brooke Schrickel, Anu Bansal, Frederik Barkhof, Cristina Besada, Sammy Chu, Jason Druzgal, Alexandru Dusoi, Luciano Farage, Fabricio Feltrin. 2023-06-01. The Brain Tumor Segmentation (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI. https://arxiv.org/abs/2306.00838

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

MarkerScout: A Disease-Agnostic Machine Learning Framework for Biomarker Prediction from Multi-Scale Mechanistic Models

We demonstrate the framework on three infectious diseases derived from a companion mechanistic immune-simulation platform: SARS-CoV-2, Influenza A Virus, and Plasmodium falciparum. Each disease was evaluated across hospitalization and intensive care unit cohorts, yielding six cohorts in total. Best-pipeline cross-validated macro F1 ranged from 0.82 for IAV-HOSP to 0.99 for COV-ICU, and the framework produced tiered, direction-aware biomarker lists for each disease and phase. Interleukin-18 (IL-18) reached the strongest tier in both SARS-CoV-2 phases with consistent direction. When benchmarked against three separate, independently collected clinical ICU datasets, MarkerScout's top-ranked features outperformed 94.4% of randomly selected feature sets of equivalent size for SARS-CoV-2, with a weaker but directionally consistent advantage for Influenza A Virus (66.7%) and Plasmodium falciparum (60.7%).

q-bio.OT

Enhancing Clinical Decision Support and Differential Diagnosis with Knowledge Graphs, and Retrieval Augmented Generation in Generative AI

Diagnostic error carries a burden, while unconstrained large language models (LLMs) remain vulnerable to hallucination and weak integration of quantitative laboratory dynamics. We developed a decision-support pipeline combining disease-specific biomarker correlation graphs, ordinary differential equations (ODEs), deep sequence classification, and retrieval-augmented generation (RAG). For 103 disease classes from a full blood count (FBC) repository, biomarker networks were used as coupling matrices to generate 30 trajectories per disease (3,090 total). A one-dimensional convolutional neural network (CNN) and long short-term memory (LSTM) network classified disease trajectories and six dynamical clusters. A constrained GPT-4o-mini RAG layer used a 19-pattern BMJ Best Practice/NICE corpus to generate differential diagnoses evaluated for diagnostic suitability, evidential grounding, and clinical plausibility. Across five random-seed runs, disease-level accuracy was $0.940 \pm 0.006$ for the CNN (95\% CI 0.933--0.948) and $0.852 \pm 0.019$ for the LSTM (95\% CI 0.828--0.875); the CNN advantage was 8.87 percentage points (95\% CI 6.47--11.27; $t(4)=10.26$, $p=5.1\times10^{-4}$; Hedges' $g=3.67$). Among 100 sampled RAG cases, 96 parsed successfully; evidence was cited in 97.9\%, the true diagnosis was mentioned in 71.9\%, and the composite score was 3.82/5 with a 47.9\% strict pass rate. The central finding was a decoupling between grounding and diagnostic correctness: classifier-correct versus classifier-wrong outputs differed in diagnostic suitability but not evidential grounding. Post-hoc analysis confirmed a 1.02-point diagnostic-score difference (Mann--Whitney $p=0.0024$; Hedges' $g=0.72$), whereas grounding differed by only $-0.02$ points ($p=0.839$; $g=-0.04$).

q-bio.OT

Expanding the Human Ancestry Ontology to include under-represented populations and ethnicities for broader utility in annotations

Successful discovery, integration and reuse of data relies on the availability of rich, well-structured and machine-readable metadata to describe every aspect of the data, from sample sources to collection processes to experimental protocols. The use of standardised terminologies to express concepts in a harmonised fashion lies at the core of high-quality data annotation, increasing the FAIRness of the data, facilitating data integration and promoting reproducibility. Here, we describe the Human Ancestry Ontology (HANCESTRO), originally developed to improve standardised reporting of genetic ancestry genomic resources such as the NHGRI-EBI GWAS Catalog and the Human Cell Atlas through high-level population descriptors, and more recently expanded to include diverse and previously under-represented populations in genomics and genetics research. HANCESTRO provides a framework for population descriptors that includes both ancestry based on the analysis of genetic information and self-reported ethnicity, which is based on social and cultural factors that don't necessarily align with genetic populations. By enabling the accurate and interoperable representation of population-related data, it promotes inclusive, representative and reproducible science.

q-bio.OT